Wenzhou Kangning Hospital 과거 수익 실적
과거 기준 확인 2/6
Wenzhou Kangning Hospital's earnings have been declining at an average annual rate of -9%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 15.3% per year. Wenzhou Kangning Hospital's return on equity is 5.8%, and it has net margins of 5.6%.
주요 정보
-9.0%
수익 성장률
-9.6%
EPS 성장률
Healthcare 산업 성장 | 11.3% |
매출 성장률 | 15.3% |
자기자본 수익률 | 5.8% |
순이익 | 5.6% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Share Price Matching Investor Opinion
Sep 26We Think The Compensation For Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) CEO Looks About Right
May 23Estimating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Feb 28Investors Continue Waiting On Sidelines For Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Jan 19Wenzhou Kangning Hospital (HKG:2120) Has A Somewhat Strained Balance Sheet
Nov 23Wenzhou Kangning Hospital (HKG:2120) Could Be Struggling To Allocate Capital
Jun 16Returns Are Gaining Momentum At Wenzhou Kangning Hospital (HKG:2120)
Mar 23Is Wenzhou Kangning Hospital (HKG:2120) Using Too Much Debt?
Dec 06Returns On Capital Are Showing Encouraging Signs At Wenzhou Kangning Hospital (HKG:2120)
Aug 11Calculating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Jul 09Wenzhou Kangning Hospital (HKG:2120) Is Experiencing Growth In Returns On Capital
May 12Wenzhou Kangning Hospital (HKG:2120) Has A Pretty Healthy Balance Sheet
Apr 10Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Feb 25Will Wenzhou Kangning Hospital (HKG:2120) Multiply In Value Going Forward?
Jan 17Should You Use Wenzhou Kangning Hospital's (HKG:2120) Statutory Earnings To Analyse It?
Dec 23If You Had Bought Wenzhou Kangning Hospital's (HKG:2120) Shares Five Years Ago You Would Be Down 42%
Dec 10Can Mixed Fundamentals Have A Negative Impact on Wenzhou Kangning Hospital Co., Ltd. (HKG:2120) Current Share Price Momentum?
Nov 27수익 및 비용 분석
Wenzhou Kangning Hospital 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 1,647 | 93 | 225 | 35 |
31 Mar 24 | 1,622 | 89 | 225 | 34 |
31 Dec 23 | 1,596 | 86 | 225 | 32 |
30 Sep 23 | 1,560 | 33 | 229 | 33 |
30 Jun 23 | 1,525 | -19 | 233 | 33 |
31 Mar 23 | 1,505 | -22 | 228 | 33 |
31 Dec 22 | 1,485 | -24 | 224 | 33 |
30 Sep 22 | 1,456 | 12 | 213 | 32 |
30 Jun 22 | 1,428 | 48 | 203 | 31 |
31 Mar 22 | 1,363 | 46 | 192 | 30 |
31 Dec 21 | 1,297 | 44 | 182 | 28 |
30 Sep 21 | 1,207 | 45 | 155 | 29 |
30 Jun 21 | 1,132 | 54 | 139 | 30 |
31 Mar 21 | 1,060 | 55 | 136 | 26 |
31 Dec 20 | 989 | 56 | 133 | 21 |
30 Sep 20 | 968 | 49 | 148 | 14 |
30 Jun 20 | 947 | 42 | 162 | 6 |
31 Mar 20 | 904 | 49 | 157 | 6 |
31 Dec 19 | 861 | 57 | 152 | 6 |
30 Sep 19 | 814 | 74 | 139 | 7 |
30 Jun 19 | 768 | 91 | 126 | 8 |
31 Mar 19 | 757 | 86 | 124 | 7 |
31 Dec 18 | 746 | 81 | 122 | 6 |
30 Sep 18 | 743 | 73 | 123 | 4 |
30 Jun 18 | 740 | 65 | 123 | 2 |
31 Mar 18 | 703 | 57 | 115 | 2 |
31 Dec 17 | 666 | 49 | 107 | 2 |
30 Sep 17 | 588 | 58 | 92 | 1 |
30 Jun 17 | 509 | 67 | 77 | 0 |
31 Mar 17 | 462 | 68 | 77 | 0 |
31 Dec 16 | 415 | 69 | 77 | 0 |
30 Sep 16 | 394 | 62 | 79 | 0 |
30 Jun 16 | 373 | 55 | 81 | 0 |
31 Mar 16 | 358 | 55 | 73 | 0 |
31 Dec 15 | 344 | 56 | 64 | 0 |
30 Sep 15 | 332 | 56 | 59 | 0 |
30 Jun 15 | 319 | 56 | 53 | 0 |
31 Mar 15 | 308 | 54 | 50 | 0 |
31 Dec 14 | 296 | 51 | 48 | 0 |
31 Dec 13 | 226 | 36 | 39 | 0 |
양질의 수익: 2120 has high quality earnings.
이익 마진 증가: 2120 became profitable in the past.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 2120's earnings have declined by 9% per year over the past 5 years.
성장 가속화: 2120 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
수익 대 산업: 2120 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-16.9%).
자기자본 수익률
높은 ROE: 2120's Return on Equity (5.8%) is considered low.